Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00990288 · ClinicalTrials.gov registry record · Phase 4
The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery
A Phase 4 study, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 4
- Development phase
- 196
- Enrollment target
NCT00990288 is a Phase 4 study that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 196 participants.
The verdict
NCT00990288, a Phase 4 study, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 196 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the agent, Floseal, can decrease the amount of blood patients lose after total knee replacement (TKR) surgery. If this product can be found to have an effect on bleeding, it may potentially reduce the problems associated with bleeding after knee replacement surgery such as pain, stiffness, and the need to have a blood transfusion. The subject's overall participation will be over a period of 6 weeks.
Interventions
- DRUG Hemostatic Matrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00990288
The ClinicalTrials.gov registry entry for NCT00990288 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hemostatic Matrix is the first listed.
NCT00990288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00990288 about?
NCT00990288 is a clinical study titled "The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery". The purpose of this study is to determine if the agent, Floseal, can decrease the amount of blood patients lose after total knee replacement (TKR) surgery. If this product can be found to have an effect on bleeding, it may potentially reduce the problems associated with bleeding after knee replaceme...
What is the current status of trial NCT00990288?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 196 participants. The study started on 2007-10. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00990288?
The interventions under investigation include: Hemostatic Matrix (DRUG).
Who is sponsoring clinical trial NCT00990288?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.